Holen Sie sich die Stockscreener-App
9.85
0.51%
0.05
Schlusskurs vom Vortag:
$9.80
Offen:
$9.41
24-Stunden-Volumen:
11,002
Relative Volume:
0.01
Marktkapitalisierung:
$14.15M
Einnahmen:
$71,000
Nettoeinkommen (Verlust:
$-2.47M
KGV:
-0.2993
EPS:
-32.9143
Netto-Cashflow:
$-5.24M
1W Leistung:
+7.07%
1M Leistung:
-2.28%
6M Leistung:
-23.82%
1J Leistung:
-54.49%
1-Tages-Spanne:
$9.41
$9.92
1-Wochen-Bereich:
$8.512
$9.92
52-Wochen-Spanne:
$6.00
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
9.90 | 14.00M | 71,000 | -2.47M | -5.24M | -32.91 |
ABT
Abbott Laboratories
|
102.47 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.77 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.72 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.40 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
Fundamentals Check: Is PAVmed Inc a potential multi baggerWeekly Profit Recap & High Conviction Buy Zone Picks - baoquankhu1.vn
PAVmed (PAVM) upgraded to buy: Here's what you should know - MSN
PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Re - gurufocus.com
PAVmed Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-03-30 - Seeking Alpha
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - Yahoo! Finance Canada
PAVM: Q4 2025 featured diagnostic revenue growth, a VA contract, and improved non-GAAP loss per share - TradingView
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
PAVmed completes $45M financing, eliminates convertible debt By Investing.com - ca.investing.com
Earnings call transcript: PAVmed Q4 2025 shows restructuring gains - Investing.com
PAVM: Restructuring and growth initiatives drive commercial momentum and financial stability - TradingView
PAVmed Reports Q4 2025 Financial Results with Key Metrics - Intellectia AI
PAVmed Reports 2025 Results, Strengthens Balance Sheet - TipRanks
Q4 2025 PAVmed Inc Earnings Call Transcript - gurufocus.com
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - stocktitan.net
PAVM: Q4 2025 featured capital restructuring, expanded diagnostics, and improved financials - TradingView
Press Release: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - news.futunn.com
PAVmed Q2 2025 Earnings Preview - MSN
PAVmed Inc. 8-K Filing Details: Company Information, Nasdaq Listing, and 2026 Shareholder Meeting Results - Minichart
PAVmed Inc. 2025 Annual Report: Financials, Risk Factors, and Corporate Governance Overview - Minichart
Bear Alert: Whats next for PAVmed Inc stock2026 Sector Moves & Safe Capital Growth Tips - baoquankhu1.vn
PAVmed's Capital Cleanup Hides High-Reward Catalyst for Patient Biotech Investors - Bitget
PAVmed Shareholders Approve Equity Issuance and Governance Changes - TipRanks
PAVmed shareholders approve stock issuance, charter amendment, and equity plan changes - Investing.com UK
PAVmed (NASDAQ: PAVM) holders approve stock issuances and expand equity plan - stocktitan.net
PAVmed 2025 10-K: Revenue $0.1M; loss before noncontrolling interests ~$2.5M - TradingView
PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PAVmed Inc Extraordinary Shareholders Meeting Transcript - gurufocus.com
What To Expect From PAVmed Inc (PAVM) Q4 2025 Earnings - gurufocus.com
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Lucid Diagnostics Reports 2025 Financial Results, Expands EsoGuard Access with VA Contract and Positive Real-World Data - Minichart
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - in.investing.com
Canaccord reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - in.investing.com
Lucid Diagnostics Reports Q4 2025 Results, Highlights VA Contract - TipRanks
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract - Investing.com
Canaccord reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics (Nasdaq: LUCD) reports 2025 loss, VA contract win - stocktitan.net
Press Release: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Insider Sell: Will PAVmed Inc stock hit new highs in YEAR2026 Pullbacks & Low Risk Entry Point Tips - baoquankhu1.vn
Lucid Diagnostics (NASDAQ: LUCD) adds $25M ATM to $175M shelf - Stock Titan
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PAVmed Q4 2025 earnings preview - MSN
PAVmed (PAVM.US) is scheduled to release its earnings report before the market opens on March 30. - Moomoo
If You Invested $1,000 in Lucid Diagnostics Inc. (LUCD) - Stock Titan
Aug Shorts: Can PAVmed Inc expand into new markets2026 Fundamental Recap & Stock Portfolio Risk Management - baoquankhu1.vn
PAVM.O Technical Analysis & Stock Price Forecast - Intellectia AI
Levels Update: Can PAVmed Inc maintain its current growth rate2026 Major Catalysts & AI Driven Price Predictions - baoquankhu1.vn
PAVmed: Fundamental Analysis and Financial Ratings | 1P50 | US70387R4039 - marketscreener.com
PAVMED announces 1-for-30 reverse stock split - MSN
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):